In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
All content for The Analytical Wavelength is the property of ACD/Labs and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
Protecting Heart Health with hERG Inhibition Prediction
The Analytical Wavelength
22 minutes
2 years ago
Protecting Heart Health with hERG Inhibition Prediction
Developing safe medicines is hard work. Researchers must rigorously assess every drug candidate molecule to ensure it does not harm patients. Cardiotoxicity - toxicity to the heart - is one of the factors that scientists consider.Members of the ACD/Labs team, Kiril Lanevskij, Remigijus Didziapetris, and Andrius Sazonovas recently published a paper on the subject of predicting hERG inhibition, a property critical for assessing cardiotoxicity. This conversation with Andrius and Kiril discusses ...
The Analytical Wavelength
In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
